The Safety and Efficacy of a SinuSonic Intervention

Nasal Congestion Clinical Trial

Official title:

SinuSonic Study for Adults With Nasal Congestion

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03906968
• Other study ID #: Pro00083883
• Status: Completed
• Phase: N/A
• Start date: March 31, 2019
• Est. completion date: December 16, 2019

Study information

• Verified date: April 2021
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to test the safety and effectiveness of the SinuSonic device on adults with moderate to severe nasal congestion. SinuSonic is a medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. This device is held over the nose for 3 minutes. This study will use patient responses to measure how effective SinuSonic devices are in treating these moderate to severe congestion in adults. The study will consist of 40 subjects at the Medical University of South Carolina and will take place over the course of 4 to 6 weeks starting with a baseline assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 16, 2019
• Est. primary completion date: December 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults =18 years of age

2. Complaints of nasal congestion present for 2 weeks or more and a qualifying nasal congestion score of >5 (10 point VAS scale)

Exclusion Criteria:

1. Fixed structural cause of nasal congestion (moderate or severe septal deviation, moderate or severe nasal valve collapse, Grade 3-4 polyp)

2. Inability to read and understand English

3. Allergic sensitivity to silicone or any other component of device

4. History of severe nose bleeding within last 3 months

5. Anticoagulation (Aspirin is acceptable)

6. Known pregnancy

7. Current nasal crusting or ulceration revealed on rhinoscopy

8. Inability to perform treatment due to underlying medical condition

9. Topical decongestant use in last week

Related Conditions & MeSH terms

• Nasal Congestion

Intervention

Device:
• SinuSonic Device
A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion

Locations

Country	Name	City	State
United States	Sinus Center - Medical Univesity of South Carolina	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety Descriptive About Occurrence of Adverse Events	Safety will be evaluated by the Adverse events occurence	4 to 6 Weeks
Other	Evaluation of Results of General Physical Examination	Collection of safety data throughout the whole study period	4 to 6 Weeks
Primary	Change in Total Nasal Symptom Score (TNSS) at 4 to 6 Weeks	Change from baseline to week 6 in subject congestion symptom severity, as measured by the Total Nasal Symptom Score (TNSS, range 0-3). Where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. TNSS is calculated by adding the score for each of the symptoms to a total out of 15.	Total Nasal Symptom Score (TNSS) at 4 to 6 Weeks
Secondary	Change in Peak Nasal Inspiratory Flow Test (PNIF Test)	Change from baseline to week 2 in subject nasal airway obstruction, as measure by the Peak Nasal Inspiratory Flow Test (PNIF Test). The PNIF is used to diagnose the patency of the nose.	Peak Nasal Inspiratory Flow Test (PNIF Test) score at 2 Weeks
Secondary	Change in Sinonasal Outcome Test 22 (SNOT-22) Total Score	Change from baseline to week 6 in subject symptoms and functioning, as measured by Sinonasal Outcome Test - 22 (SNOT-22). SNOT-22 is a subject-completed questionnaire that consists of 22 questions. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be. The total score can range from 0-110, 0 being the best and 110 being the worst.	Sinonasal Outcome Test 22 (SNOT-22) Total Score at 4 to 6 Weeks
Secondary	Change in Visual Analog Scale (VAS)	The visual analog scale (VAS) for rhinosinusitis is used to evaluate the total severity. The subject is asked to indicate on a VAS the answer to the question: "How troublesome are your symptoms of rhinosinusitis?" Subject will assess Nasal symptoms using a 10 cm Visual Analog Scale for each symptom, 0=not troublesome and 10 = the worst imaginable. The disease can be divided into Mild, Moderate and Severe based on total severity VAS score (0 to 10 cm): Mild = VAS 0-3; Moderate = VAS > 3-7; Severe = VAS > 7-10	Visual Analog Scale (VAS) score at 4 to 6 Weeks
Secondary	Change in Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE Scale)	Change from baseline to week 6 in subject nasal congestion severity, as measured by the Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE Scale). The NOSE scale is a subject-completed questionnaire that consists of 5 questions. Each item is rated as follows: 0=not a problem, 1=very mild problem, 2=moderate problem, 3=fairly bad problem, 4=severe problem. The total score can range from 0-100, 0 being the best and 100 being the worst.	Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE Scale) score at 4 to 6 Weeks